Novel Echocardiographic Measurements of Right Ventricular-Pulmonary Artery Coupling in Predicting the Prognosis of Precapillary Pulmonary Hypertension

Overview

Journal J Pers Med

Date 2023 Dec 23

PMID 38138854

Authors

Weronika Topyla-Putowska

Michal Tomaszewski

Agnieszka Wojtkowska

Andrzej Wysokinski

Affiliations

Soon will be listed here.

Abstract

Background: Currently, there are many parameters with proven prognostic significance in pulmonary hypertension (PH). Recently, the parameters defining right ventricular-pulmonary artery coupling (RVPAC) have gained clinical importance. In our study, we investigated the prognostic potential of previously known single echocardiographic parameters and new parameters reflecting RVPAC in patients with precapillary PH.

Objective: Our study aimed to evaluate the prognostic value of selected echocardiographic parameters and the neutrophil-lymphocyte ratio (NLR) in adults with precapillary PH.

Methods: This study included 39 patients (74% women; average age, 63 years) with precapillary PH: pulmonary arterial hypertension (PAH) and chronic thromboembolic PH (CTEPH). The mean follow-up period was 16.6 ± 13.3 months. Twelve patients (31%) died during the observation time. We measured several echocardiographic parameters, which reflect right ventricular function, pulmonary hemodynamics, and RVPAC. To assess disease progression and the patient's functional capacity, the World Health Organization functional class (WHO FC) was determined. The patient's physical capacity was also evaluated using the 6 min walk test (6MWT). The analysis included values of the N-terminal prohormone brain natriuretic peptide (NT-proBNP) and NLR.

Results: TAPSE × AcT and TAPSE/sPAP were shown to statistically and significantly correlate with PH predictors, including WHO-FC, 6MWT, and NT-proBNP. Univariate Cox proportional hazards regression analysis revealed that AcT, TAPSE, mPAP, TAPSE/sPAP, RAP, TRPG/AcT, TAPSE × AcT, and NLRs are good predictors of mortality in patients with PH. In addition, the ROC curve analysis showed that TAPSE × AcT is a better predictor of PH-related deaths than TAPSE/sPAP and TAPSE alone. In our study, patients with TAPSE × AcT values < 126.36 had shorter survival times (sensitivity = 72.7%; specificity = 80.0%).

Conclusions: TAPSE × AcT is a novel, promising, and practicable echocardiographic parameter reflecting RVPAC, which is comparable to TAPSE/sPAP. Moreover, TAPSE × AcT can be a useful parameter in assessing the severity and prognosis of patients with precapillary PH.

Citing Articles

The value of right ventricular pulmonary artery coupling in determining the prognosis of patients with sepsis.

Ma Q, Ding C, Wei W, Su C, Li B, Zhou Z Sci Rep. 2024; 14(1):15283.

PMID: 38961249 PMC: 11222489. DOI: 10.1038/s41598-024-65738-2.

References

Colak A, Kumral Z, Kis M, Senturk B, Sezgin D, Omeroglu Simsek G . The Usefulness of the TAPSE/sPAP Ratio for Predicting Survival in Medically Treated Chronic Thromboembolic Pulmonary Hypertension. Turk Kardiyol Dern Ars. 2023; 51(7):470-477. DOI: 10.5543/tkda.2023.78074. View

Simonneau G, Montani D, Celermajer D, Denton C, Gatzoulis M, Krowka M . Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2018; 53(1). PMC: 6351336. DOI: 10.1183/13993003.01913-2018. View

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

Schmid E, Hilberath J, Blumenstock G, Shekar P, Kling S, Shernan S . Tricuspid annular plane systolic excursion (TAPSE) predicts poor outcome in patients undergoing acute pulmonary embolectomy. Heart Lung Vessel. 2015; 7(2):151-158. PMC: 4476769. View

Rich J, Shah S, Swamy R, Kamp A, Rich S . Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest. 2010; 139(5):988-993. DOI: 10.1378/chest.10-1269. View

Souza R, Channick R, Delcroix M, Galie N, Ghofrani H, Jansa P . Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. PLoS One. 2018; 13(3):e0193226. PMC: 5873992. DOI: 10.1371/journal.pone.0193226. View

Aubert R, Venner C, Huttin O, Haine D, Filippetti L, Guillaumot A . Three-Dimensional Echocardiography for the Assessment of Right Ventriculo-Arterial Coupling. J Am Soc Echocardiogr. 2018; 31(8):905-915. DOI: 10.1016/j.echo.2018.04.013. View

Bousseau S, Sobrano Fais R, Gu S, Frump A, Lahm T . Pathophysiology and new advances in pulmonary hypertension. BMJ Med. 2023; 2(1):e000137. PMC: 10083754. DOI: 10.1136/bmjmed-2022-000137. View

Balakrishnan B, Owens B, Hayes R, Wen S . A Systematic Review of Echocardiographic Parameters for the Screening of Pulmonary Hypertension: What Are the Odds?. Cureus. 2023; 14(12):e32185. PMC: 9810508. DOI: 10.7759/cureus.32185. View

10.

Tello K, Wan J, Dalmer A, Vanderpool R, Ghofrani H, Naeije R . Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension. Circ Cardiovasc Imaging. 2019; 12(9):e009047. PMC: 7099862. DOI: 10.1161/CIRCIMAGING.119.009047. View

11.

Simons J, Mann E, Pierozynski A . Assessment of Risk of Disease Progression in Pulmonary Arterial Hypertension: Insights from an International Survey of Clinical Practice. Adv Ther. 2019; 36(9):2351-2363. PMC: 6822842. DOI: 10.1007/s12325-019-01030-4. View

12.

Fisher M, Forfia P, Chamera E, Housten-Harris T, Champion H, Girgis R . Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009; 179(7):615-21. PMC: 2720125. DOI: 10.1164/rccm.200811-1691OC. View

13.

Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G . Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017; 50(2). DOI: 10.1183/13993003.00889-2017. View

14.

Taniguchi T, Ohtani T, Nakatani S, Hayashi K, Yamaguchi O, Komuro I . Impact of Body Size on Inferior Vena Cava Parameters for Estimating Right Atrial Pressure: A Need for Standardization?. J Am Soc Echocardiogr. 2015; 28(12):1420-7. DOI: 10.1016/j.echo.2015.07.008. View

15.

Gall H, Felix J, Schneck F, Milger K, Sommer N, Voswinckel R . The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. J Heart Lung Transplant. 2017; 36(9):957-967. DOI: 10.1016/j.healun.2017.02.016. View

16.

Tello K, Axmann J, Ghofrani H, Naeije R, Narcin N, Rieth A . Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension. Int J Cardiol. 2018; 266:229-235. DOI: 10.1016/j.ijcard.2018.01.053. View

17.

DAlto M, Bossone E, Opotowsky A, Ghio S, Rudski L, Naeije R . Strengths and weaknesses of echocardiography for the diagnosis of pulmonary hypertension. Int J Cardiol. 2018; 263:177-183. DOI: 10.1016/j.ijcard.2018.04.024. View

18.

Ozpelit E, Akdeniz B, Ozpelit M, Tas S, Bozkurt S, Tertemiz K . Prognostic value of neutrophil-to-lymphocyte ratio in pulmonary arterial hypertension. J Int Med Res. 2015; 43(5):661-71. DOI: 10.1177/0300060515589394. View

19.

More K, Soni R, Gupta S . The role of bedside functional echocardiography in the assessment and management of pulmonary hypertension. Semin Fetal Neonatal Med. 2022; 27(4):101366. DOI: 10.1016/j.siny.2022.101366. View

20.

Tsarova K, Morgan A, Melendres-Groves L, Ibrahim M, Ma C, Pan I . Imaging in Pulmonary Vascular Disease-Understanding Right Ventricle-Pulmonary Artery Coupling. Compr Physiol. 2022; 12(4):3705-3730. DOI: 10.1002/cphy.c210017. View